Entropy Technologies LP purchased a new position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 41,500 shares of the biopharmaceutical company's stock, valued at approximately $462,000.
Other hedge funds have also made changes to their positions in the company. Assenagon Asset Management S.A. bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth approximately $8,291,000. Millennium Management LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter worth approximately $17,615,000. Vanguard Group Inc. lifted its holdings in shares of Dynavax Technologies by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company's stock worth $116,682,000 after purchasing an additional 126,458 shares during the last quarter. AlphaCentric Advisors LLC lifted its holdings in shares of Dynavax Technologies by 55.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 201,500 shares of the biopharmaceutical company's stock worth $2,245,000 after purchasing an additional 71,500 shares during the last quarter. Finally, Bank of Montreal Can raised its stake in Dynavax Technologies by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company's stock valued at $11,309,000 after acquiring an additional 130,893 shares in the last quarter. Institutional investors own 96.96% of the company's stock.
Dynavax Technologies Stock Performance
Dynavax Technologies stock traded down $1.18 during mid-day trading on Friday, hitting $12.21. 8,112,419 shares of the company's stock traded hands, compared to its average volume of 2,172,531. The firm has a 50 day moving average price of $11.39 and a 200 day moving average price of $11.31. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.61 billion, a PE ratio of 93.92 and a beta of 1.34. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Friday, November 8th. The Goldman Sachs Group cut their target price on Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th.
Read Our Latest Stock Analysis on Dynavax Technologies
Dynavax Technologies Company Profile
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Further Reading
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
